Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Soins. Pediatrie, Puericulture
|
September 1, 1996
[Maturity and critical situations]
L Dine
Journal of Cultural Diversity
|
February 1, 2012
Nursing education on lymphedema self-management and self-monitoring in a South African oncology clinic
Jennifer L Dine, Melanie K Schneider Austin, Jane M Armer
Cells
|
December 11, 2022
Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy
Manjari Kundu, Yoshimi Endo Greer, Jennifer L Dine, et al.
Breast Cancer Research : BCR
|
April 22, 2014
Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening
Sireesha V Garimella, Kristie Gehlhaus, Jennifer L Dine, et al.
Breast Cancer Research and Treatment
|
January 14, 2016
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl
Jennifer L Dine, Ciara C O'Sullivan, Donna Voeller, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Soins. Pediatrie, Puericulture
|
September 1, 1996
[Maturity and critical situations]
L Dine
Journal of Cultural Diversity
|
February 1, 2012
Nursing education on lymphedema self-management and self-monitoring in a South African oncology clinic
Jennifer L Dine, Melanie K Schneider Austin, Jane M Armer
Cells
|
December 11, 2022
Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy
Manjari Kundu, Yoshimi Endo Greer, Jennifer L Dine, et al.
Breast Cancer Research : BCR
|
April 22, 2014
Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening
Sireesha V Garimella, Kristie Gehlhaus, Jennifer L Dine, et al.
Breast Cancer Research and Treatment
|
January 14, 2016
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl
Jennifer L Dine, Ciara C O'Sullivan, Donna Voeller, et al.
Page
of 1